62.49 In Stock
Primary glomerulonephritis is one of the most frequent renal diseases, and a main cause of end-stage kidney disease. Glomerulonephritis has multiple subtypes, each with different physiopathologies, clinical presentations, and management requirements, which makes treatment difficult. As a complex set of diseases, the choice of symptomatic and specific treatment is critical to ameliorating the relentless course of glomerulonephritis. Focusing on all aspects of primary glomerulonephritis, from their epidemiologies and classification, to their pathogenesis and treatment, this third edition of Treatment of Primary Glomerulonephritis has been fully updated to include the latest research and evidence-based practice. With a strong emphasis on drugs used for both symptomatic and specific treatments, mechanisms of action, effectiveness, and potential toxicity are considered for therapeutic strategies in the different subtypes of primary glomerulonephritis. Each chapter follows a clear and logical format, allowing easy access to key information. Featuring over 20 full-colour histological images of different diseases to aid diagnosis, and with commentary from internationally recognised experts in the field, this new edition is an essential resource for all practising or academic clinical nephrologists.
About the Author
Claudio Ponticelli is an acknowledged expert in the field of nephrology, particularly in glomerular diseases and kidney transplantation. In glomerular diseases, he devised an original therapeutic schedule in primary membranous nephropathy, and has also co-ordinated randomised clinical trials in minimal change disease, focal glomerular sclerosis, and IgA nephropathy. During his career, Professor Ponticelli has been a member of the Council of the Italian Society of Nephrology, the Italian-American Society of Nephrology, and served as the President of the Italian Society of Nephrology. He has received numerous awards, including the ERA/EDTA Award for outstanding scientific achievements. Richard J. Glassock is an internationally recognised expert in the field of glomerular diseases and clinical nephrology. Currently Professor Emeritus at the David Geffen School of Medicine at UCLA, he is the past-president of the American Society of Nephrology, the National Kidney Foundation (USA), and past-Chairman of the American Board of Internal Medicine. Over his career he has been a visiting professor at over 100 academic institutions, and founded the NephSAP Journal of the American Society of Nephrology as Editor-in-Chief. He has received numerous awards and distinguished lectureships, including the David Hume Memorial Award of the National Kidney Foundation.
Table of Contents1. A definition, modern classification, and global epidemiology of primary glomerulonephritis, Claudio Ponticelli and Richard Glassock
2. Symptomatic therapy, Richard Glassock
3. The pharmacology of old and new agents for specific therapy of primary glomerular diseases, Claudio Ponticelli and Richard Glassock
4. Minimal change disease, Claudio Ponticelli, Richard Glassock, and Rosanna Coppo
5. Focal and segmental glomerular sclerosis, Claudio Ponticelli, Richard Glassock, and Francesco Scolari
6. Membranous nephropathy, Claudio Ponticelli, Richard Glassock, and Patrizia Passerini
7. Immunoglobulin A nephropathy, Richard Glassock, Claudio Ponticelli, and Kar Neng Lai
8. Infection-related and renal-limited glomerulonephritis, Richard Glassock, Lee Hebert, Gabriella Moroni, and Claudio Ponticelli
9. C3 Glomerulopathies and 'idiopathic' immune complex membranoproliferative glomerulonephritis, Richard Glassock and Fernando C. Fervenza
10. Renal-limited vasculitis, Richard Glassock and Patrick Nachman
11. Other primary glomerular diseases, Claudio Ponticelli and Gabriella Moroni